Abstract: The methods and compositions described herein relate to the identification, isolation, and characterization of genes which encode proteins useful for the biosynthesis of transglycosylase inhibitors such as moes. The methods and compositions also relate to the production of such proteins, and their use in the synthesis of moes, the expression of moes, and the production of modified moes.

Abstract: The methods and compositions described herein relate to the identification, isolation, and characterization of genes which encode proteins useful for the biosynthesis of transglycosylase inhibitors such as moes. The methods and compositions also relate to the production of such proteins, and their use in the synthesis of moes, the expression of moes, and the production of modified moes.

Abstract: The present invention relates to crystals of the Escherichia coli MurG, a membrane-associated UDP-glycosyltransferase involved in peptidoglycan biosynthesis. The present invention also relates to three-dimensional atomic coordinates of the MurG protein, three-dimensional structures of the protein, and images thereof. The present invention relates to methods of crystallizing MurG proteins.

Abstract: Compounds that are analogs of glycopeptide antibiotics are disclosed. The compounds have the formula A1-A2-A3-A4-A5-A6-A7 wherein each of the groups A2 to A7 is a modified or unmodified &agr;-amino acid residue, A1 is optional and, when present, is an organic group other than N-substituted leucine, and at least one of the groups A1 to A7 is linked via a glycosidic bond to one or more glycosidic groups each having one or more sugar residues, wherein at least one of said sugar residues is modified to bear at least one hydrophobic substituent. Methods of making these compounds, compositions including these compounds, and methods of using the compounds to treat infections in a host are also disclosed.

Abstract: Compounds that are vancomycin analogs bearing terminal carboxyl group modifications as well as modifications to the vancosamine nitrogen and, optionally, modifications to the C6 position of the glucose residue attached to the amino acid four of the vancomycin heptapeptide chain are disclosed. Methods of making the compounds and methods of using the compounds to treat a bacterial infection in a host are also disclosed.

Abstract: The present invention relates to crystals of the Escherichia coli MurG, a membrane-associated UDP-glycosyltransferase involved in peptidoglycan biosynthesis. The present invention also relates to three-dimensional atomic coordinates of the MurG protein, three-dimensional structures of the protein, and images thereof. The present invention also relates to the atomic coordinates and three-dimensional structures of the &agr;-carbon backbone and of the &agr;-carbon backbone and conserved amino acid residue sidechains of the MurG protein and images thereof. The present invention further relates to three-dimensional atomic coordinates of the donor nucleotide binding site, the acceptor binding site, and the membrane association site of the MurG protein, three-dimensional structures of the binding domains, and images thereof. The present invention also relates to computer readable media encoded with sets of the three dimensional coordinates described herein.

Abstract: Compounds that are analogs of glycopeptide antibiotics are disclosed. The compounds have the formula A1-A2-A3-A4-A5-A6-A7 wherein each of the groups A2 to A7 is a modified or unmodified &agr;-amino acid residue, A1 is optional and, when present, is an organic group other than N-substituted leucine, and at least one of the groups A1 to A7 is linked via a glycosidic bond to one or more glycosidic groups each having one or more sugar residues, wherein at least one of said sugar residues is modified to bear at least one hydrophobic substituent. Methods of making these compounds, compositions including these compounds, and methods of using the compounds to treat infections in a host are also disclosed.

Abstract: Compounds that are vancomycin analogs bearing terminal carboxyl group modifications as well as modifications to the vancosamine nitrogen and, optionally, modifications to the C6 position of the glucose residue attached to the amino acid four of the vancomycin heptapeptide chain are disclosed. Methods of making the compounds and methods of using the compounds to treat a bacterial infection in a host are also disclosed.